Immunoquantification of α-galactosidase: Evaluation for the diagnosis of fabry disease

Clinical Chemistry

Volumn 50, Issue 11, 2004, Pages 1979-1985

  Fuller, Maria ^a,b   Lovejoy, Melanie ^a   Brooks, Doug A ^a,b   Harkin, Miriam L ^a   Hopwood, John J ^a,b   Meikle, Peter J ^a,b  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; SPHINGOLIPID ACTIVATOR PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; FABRY DISEASE; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; LYSOSOME STORAGE DISEASE; MEASUREMENT; NEWBORN; NEWBORN SCREENING; X CHROMOSOME LINKED DISORDER;

ADULT; ALPHA-GALACTOSIDASE; BLOOD SPECIMEN COLLECTION; ENZYME TESTS; FABRY DISEASE; HUMANS; IMMUNOASSAY; INFANT, NEWBORN; NEONATAL SCREENING; SAPOSINS; SENSITIVITY AND SPECIFICITY;

EID: 7044264831     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.037937     Document Type: Article

References (19)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease: ceramide trihexosidase deficiency. N Engl J Med 1967;276:1163-7.
2. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognised multisystemic disorder: expert recommendations for diagnosis, management and enzyme replacement therapy. Ann Intern Med 2003;338-45.
3. Ishii S, Nakoa S, Minamikawa-Tachino R, Desnick RJ, Fan JQ. Alternative splicing in the α-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype. Am J Hum Genet 2002;70:994-1002.
4. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64:801-7.
5. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females [Letter]. J Med Genet 2001;38:769-75.
6. Lemansky P, Bishop DF, Desnick RJ, Hasilik A, von Figura K. Synthesis and processing of α-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease. J Biol Chem 1987;262:2062-5.
7. Matsuura F, Ohta M, Ioannou YA, Desnick RJ. Human α-galactosidase A: characterization of the N-linked oligosaccharides on the intracellular and secreted glycoforms overexpressed by Chinese hamster ovary cells. Glycobiology 1998;8:329-39.
8. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
9. Pastores GM, Thadhani R. Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 2001;358:601-3.
10. Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
11. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal α-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 1981;112:247-51.
12. Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD, et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two tier strategy. Pediatrics 2004; in press.
13. Chang MH, Bindloss CA, Grabowski GA, Qi X, Winchester B, Hopwood JJ, et al. Saposins A, B, C and D in plasma of patients with lysosomal storage disorders. Clin Chem 2000;46:167-74.
14. Meikle PJ, Brooks DA, Ravenscroft EM, Yan M, Williams RE, Jaunzems AE, et al. Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker. Clin Chem 1997;43:1325-35.
15. Whitfield PD, Nelson P, Sharp PC, Bindloss CA, Dean C, Ravenscroft EM, et al. Correlation among genotype, and phenotype, and biochemical markers in Gaucher disease: implications for the prediction of disease severity. Mol Genet Metab 2002;75:46-55.
16. Linthorst GE, Hollak CEM, Korevaar JC, van Manen JG, Aerts JMFG, Boeschoten, EW. α-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 2003;18:1581-4.
17. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Knizler KW, et al., eds. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill, 2001:3733-74.
18. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001;308:195-6.
19. Umapthysivam K, Hopwood, JJ, Meikle PJ. Determination of acid α-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem 2001;47:1378-83.